Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [5] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [5] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [3] - Over half of the company secretaries hold a bachelor's degree, with the breakdown being 9% with an associate degree, 52% with a bachelor's degree, and 39% with a master's degree [3] Top and Bottom Salaries - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.176 million yuan, and 1.0832 million yuan, respectively [7] - The three lowest-paid company secretaries earn 174,200 yuan, 187,500 yuan, and 190,700 yuan, all of whom have served in their positions for less than two years [7] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [9] - Five companies reported zero investor meetings, while the top five companies for investor engagement had between 291 and 520 meetings, with corresponding secretary salaries ranging from 267,000 yuan to 444,200 yuan [9]

Summary of Key Points Core Viewpoint - Dongya Pharmaceutical reported a decrease in the number of shareholders and a significant decline in revenue and net profit for the first quarter of the year [2] Shareholder Information - As of July 20, the number of shareholders for Dongya Pharmaceutical was 11,203, a decrease of 670 from the previous period (July 10), representing a decline of 5.64% [2] Stock Performance - The closing price of Dongya Pharmaceutical was 20.79 yuan, an increase of 0.92%, with a cumulative increase of 8.22% since the concentration of shares began. The stock experienced 9 days of increases and 4 days of decreases during this period [2] Financial Performance - In the first quarter, Dongya Pharmaceutical achieved a revenue of 191 million yuan, a year-on-year decrease of 45.85%. The net profit was -6.92 million yuan, a year-on-year decline of 128.78%, with a basic earnings per share of -0.0600 yuan [2] - On July 15, the company released a performance forecast for the first half of the year, expecting a net profit loss between -35 million yuan and -28 million yuan [2]

Core Viewpoint - Dongya Pharmaceutical (605177.SH) is expected to report a significant loss in the first half of 2025, with net profit projected to be between -28 million to -35 million yuan, contrasting sharply with a profit of 32.47 million yuan in the same period last year [1][2]. Financial Performance - In 2024, the company reported operating revenue of 1.198 billion yuan, a decrease of 11.66% year-on-year [2]. - The net profit attributable to shareholders was -101 million yuan, representing a year-on-year decline of 183.02% [2]. - The net profit after excluding non-recurring gains and losses was -98.41 million yuan, down 191.03% year-on-year [2]. - The net cash flow from operating activities was -157 million yuan [2]. Shareholder Structure - The actual controllers of Dongya Pharmaceutical are Chi Zhengming and Chi Cheng, who together hold significant voting rights in the company [1]. - Chi Zhengming directly owns 41.06% of the shares, while Chi Cheng holds 6.79% directly and has additional influence through a partnership [1]. Fundraising and Use of Proceeds - Dongya Pharmaceutical has raised a total of 1.574 billion yuan through two fundraising rounds since its listing [4]. - The company raised 688 million yuan through the issuance of convertible bonds, with a net amount of approximately 680 million yuan after deducting issuance costs [3]. - The funds raised are allocated for projects including the production of key intermediates for cephalosporin antibiotics and upgrading raw material production [2].

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. is expected to report a significant loss for the first half of 2025, with net profit projected to be between -28 million and -35 million yuan, indicating a decline compared to the same period last year [2][4]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to June 30, 2025 [3]. - The company anticipates a net profit attributable to shareholders of -28 million to -35 million yuan, which represents a loss compared to the previous year's profit of 32.47 million yuan [4][7]. - The expected net profit after deducting non-recurring gains and losses is projected to be between -33 million and -40 million yuan [5]. Group 2: Reasons for Performance Decline - The primary reason for the expected loss is attributed to a decrease in gross profit by approximately 30 million yuan due to changes in product demand influenced by global economic slowdown, industry policies, and intensified competition [10]. - The company plans to recognize an inventory impairment provision of around 30 million yuan, as the net realizable value of certain inventories is expected to be lower than their cost [11]. - Despite the challenges, the company has achieved a significant milestone by obtaining its first formulation approval, which is expected to enhance its product line and competitiveness [9].

Group 1 - The company expects a net profit loss of between 28 million to 35 million yuan for the first half of 2025, with a non-recurring net profit loss of 33 million to 40 million yuan, indicating a year-on-year decline [1] - The main reasons for the profit decline are attributed to changes in product demand due to global economic slowdown, industry policies, and increased competition, leading to a decrease in gross profit of approximately 30 million yuan [1] - The company plans to make a provision for impairment of inventory assets amounting to around 30 million yuan based on prudence [1] Group 2 - The company is actively pursuing an integrated strategy for raw materials and formulations to address challenges in the pharmaceutical industry [2] - In 2023, the company raised nearly 700 million yuan through convertible bonds, investing 350 million yuan in the construction of formulation factory capacity [2] - The company has received acceptance for eight formulation product applications by the end of 2024, with the first formulation product, levofloxacin, approved in June [2] Group 3 - The company's subsidiary, Hangzhou Shanli Biopharmaceutical Technology Co., Ltd., has received the CNAS laboratory accreditation certificate, enhancing its product quality assurance and R&D capabilities [3] - The CNAS accreditation signifies the laboratory's compliance with national standards, which may facilitate international product testing and enhance global market competitiveness [3]

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. expects a significant decline in net profit for the first half of 2025, projecting a loss between 28 million to 35 million yuan, compared to a profit of 32.47 million yuan in the same period last year [1][2]. Performance Forecast - The company anticipates a net profit attributable to shareholders of the listed company to be between -28 million yuan and -35 million yuan for the first half of 2025 [1]. - The expected net profit after deducting non-recurring gains and losses is projected to be between -33 million yuan and -40 million yuan [1]. Previous Year Performance - In the same period last year, the net profit attributable to shareholders was 32.47 million yuan, with a net profit of 26.93 million yuan after deducting non-recurring gains and losses [2]. - The earnings per share for the previous year was 0.29 yuan [2]. Reasons for Performance Decline - The decline in net profit is attributed to several factors: - **Revenue Side**: The company faced reduced demand for some products due to global economic slowdown, industry-related policies, and intensified competition, leading to a decrease in gross profit by approximately 30 million yuan [2]. - **Asset Side**: The company plans to make impairment provisions for certain assets, including inventory, due to expected realizable net values being lower than costs [2]. - Despite these challenges, the company is committed to its integrated development strategy for raw materials and formulations, aiming to enhance product lines and maintain market share [2]. Strategic Outlook - The management expresses confidence in the company's future operational development, focusing on cost reduction, organizational transformation, and improving operational quality to enhance product competitiveness and efficiency [2].

[Key Performance Forecast Data for the Current Period](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E6%83%85%E5%86%B5) The company forecasts a net loss for H1 2025, with attributable net profit between **-28 million and -35 million RMB** and non-recurring adjusted net profit between **-33 million and -40 million RMB** 2025 Half-Year Performance Forecast | Indicator | Estimated Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Shareholders | -28 million to -35 million | | Net Profit Attributable to Shareholders After Non-Recurring Items | -33 million to -40 million | - These performance forecast data are preliminary estimates by the company's finance department and have not been audited by a certified public accountant[5](index=5&type=chunk) [Prior Period Operating Performance](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8A%E5%B9%B4%E5%90%8C%E6%9C%9F%E7%BB%8F%E8%90%A5%E4%B8%9A%E7%BB%A9%E5%92%8C%E8%B4%A2%E5%8A%A1%E7%8A%B6%E5%86%B5) The company reported a profit in H1 2024, with attributable net profit of **32.473 million RMB** and non-recurring adjusted net profit of **26.9332 million RMB**, contrasting the H1 2025 forecast loss 2024 Half-Year Performance (Prior Period) | Indicator | Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Shareholders | 32.473 million | | Net Profit Attributable to Shareholders After Non-Recurring Items | 26.9332 million | | Earnings Per Share | 0.29 | [Analysis of Current Period Forecast Loss](index=2&type=section&id=%E4%B8%89%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E4%BA%8F%E7%9A%84%E4%B8%BB%E8%A6%81%E5%8E%9F%E5%9B%A0) The company's shift to a loss is primarily due to a **30 million RMB** decrease in gross profit from reduced market demand and an estimated **30 million RMB** inventory impairment provision [Revenue Side Impact](index=2&type=section&id=%E4%B8%89%E3%80%81%EF%BC%88%E4%B8%80%EF%BC%89%E6%94%B6%E5%85%A5%E7%AB%AF) Reduced terminal demand for some products, influenced by global economic slowdown and competition, led to a year-on-year decrease of approximately **30 million RMB** in gross profit - Due to global economic slowdown, industry policies, intensified competition, supply chain dynamics, and inventory pressure, some of the company's products face reduced demand[8](index=8&type=chunk) - These factors resulted in a year-on-year decrease of approximately **30 million RMB** in the company's gross profit for the current reporting period[8](index=8&type=chunk) [Asset Side Impact](index=2&type=section&id=%E4%B8%89%E3%80%81%EF%BC%88%E4%BA%8C%EF%BC%89%E8%B5%84%E4%BA%A7%E7%AB%AF) Based on prudence, the company plans to accrue approximately **30 million RMB** in inventory impairment provisions for this period, as the net realizable value of some inventory is below cost - The company intends to accrue impairment provisions for assets that may show signs of impairment, primarily inventory[8](index=8&type=chunk) - An estimated **30 million RMB** in inventory impairment provisions is planned for the current reporting period[8](index=8&type=chunk) [Company Strategy and Countermeasures](index=2&type=section&id=%E5%85%AC%E5%8F%B8%E6%88%98%E7%95%A5%E4%B8%8E%E5%BA%94%E5%AF%B9) Despite short-term challenges, the company achieved a major strategic breakthrough with its first preparation approval, advancing its 'API-formulation integration' strategy, and is implementing cost control and organizational reforms - The company obtained its first preparation approval, marking a significant breakthrough in its 'API-formulation integration' development strategy[8](index=8&type=chunk) - The company is actively maintaining market share for its leading products, enriching its product pipeline, and fully advancing the implementation of its preparation business[9](index=9&type=chunk) - Management is implementing cost control and organizational reforms to improve operational quality and enhance product competitiveness[9](index=9&type=chunk) [Risk Warning](index=2&type=section&id=%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The company confirms no major uncertainties affecting the accuracy of this performance forecast, emphasizing that the disclosed financial data are preliminary and unaudited - The financial data contained in this announcement are preliminary calculations by the company's finance department based on prudence, and have not been audited by a certified public accountant[10](index=10&type=chunk) [Other Explanatory Notes](index=3&type=section&id=%E4%BA%94%E3%80%81%E5%85%B6%E4%BB%96%E8%AF%B4%E6%98%8E%E4%BA%8B%E9%A1%B9) The company reiterates that the forecast data are preliminary, and final accurate financial figures will be based on the officially disclosed 2025 half-year report, advising investors to be aware of investment risks - The final accurate financial data will be subject to the company's officially disclosed 2025 half-year report, reminding investors to be aware of investment risks[11](index=11&type=chunk)

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-038 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 关于全资子公司获得中国合格评定国家认可委员会（CNAS） 实验室认可证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江东亚药业股份有限公司（以下简称"公司"）全资子公司杭州善礼生物 医药科技有限公司（以下简称"杭州善礼"）于近日收到中国合格评定国家认可 委 员 会 （ 英 文 名 称 为 " China National Accreditation Service for Conformity Assessment"，以下简称"CNAS"）授予的实验室认可证书，现将相关事宜公 告如下： 一、证书内容 获得机构名称：杭州善礼生物医药科技有限公司 检验检测中心注册号：CNAS L23199 生效日期：2025 年 5 月 20 日 证书主要内容：杭州善礼生物医药科技有限公司分析实验室符合 ISO/IEC 1 ...

Core Viewpoint - East Asia Pharmaceutical (605177) announced that its wholly-owned subsidiary, Hangzhou Shanli Biomedical Technology Co., Ltd., has recently obtained the laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment, which enhances the company's credibility and competitive edge in the market [1] Group 1 - The accreditation certificate is effective from May 20, 2025, to May 19, 2031, indicating a long-term recognition of the laboratory's management and technical capabilities [1] - This recognition allows Hangzhou Shanli's analysis laboratory to conduct testing according to national standards, thereby improving product quality and research capabilities [1] - The accreditation is expected to enhance customer trust and contribute to the company's high-quality development, although it will not have a significant impact on the company's current performance [1]

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-037 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 关于可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计转股情况：截至 2025 年 6 月 30 日，累计已有人民币 23,774,000 元 "东亚转债"转为公司 A 股普通股，累计转股股数为 1,153,776 股，占"东亚转 债"转股前公司已发行普通股股份总额的 1.0156%。 未转股可转债情况：截至 2025 年 6 月 30 日，尚未转股的"东亚转债" 金额为人民币 666,226,000 元，占"东亚转债"发行总量的比例为 96.5545%。 本季度转股情况：2025 年 4 月 1 日至 2025 年 6 月 30 日，"东亚转债" 未发生转股情况。 一、"东亚转债"发行上市概况 经中国证券监督管理委员会证监许可〔2023〕1165 号文核准，浙江东亚药 ...